NewAmsterdam Pharma (NAMS) Return on Capital Employed (2024 - 2026)

NewAmsterdam Pharma has disclosed Return on Capital Employed across 3 years of filings, most recently posting 31.48% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 31.48%, down 778.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 31.48% (down 778.0% YoY), and the FY2025 annual result was 30.87%, up 447.0% from the prior year.
• Return on Capital Employed came in at 31.48% for Q1 2026 at NewAmsterdam Pharma, up from 32.61% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 22.15% in Q2 2025 to a low of 55.47% in Q1 2024.
• The 3-year median for Return on Capital Employed is 32.35% (2024), against an average of 35.59%.
• Across the five-year window, Return on Capital Employed soared 3177 bps in 2025 and tumbled 778 bps in 2026, its largest moves.
• NewAmsterdam Pharma's Return on Capital Employed stood at 32.35% in 2024, then retreated by 1 bps to 32.61% in 2025, then rose by 3 bps to 31.48% in 2026.
• The last three Return on Capital Employed figures came in at 31.48% (Q1 2026), 32.61% (Q4 2025), and 27.33% (Q3 2025), per Business Quant data.